Stock 6661 WELGENE BIOTECH CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Welgene Biotech Co.,Ltd.

Equities

6661

TW0006661002

Biotechnology & Medical Research

End-of-day quote Taipei Exchange
Other stock markets
 23:00:00 30/05/2024 BST 		5-day change 1st Jan Change
22.8 TWD +0.66% Intraday chart for Welgene Biotech Co.,Ltd. +0.88% +2.01%
05-09 Welgene Biotech Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-14 Welgene Biotech Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 423.4 579.7 749.5 569.8 517.4 520.8
Enterprise Value (EV) 1 281.7 431.7 597.5 370.1 351 478.1
P/E ratio 15 x 18.9 x 25.3 x 41.4 x 54.2 x -197 x
Yield 6.17% 4.79% 3.04% 1.98% 0.81% -
Capitalization / Revenue 1.1 x 1.39 x 1.88 x 1.82 x 1.61 x 1.86 x
EV / Revenue 0.73 x 1.03 x 1.5 x 1.18 x 1.09 x 1.7 x
EV / EBITDA 6.08 x 9.41 x 14.1 x 16.7 x 14.4 x 50.4 x
EV / FCF 9.82 x 6.12 x 19.7 x 173 x 13.5 x -27.8 x
FCF Yield 10.2% 16.3% 5.07% 0.58% 7.38% -3.59%
Price to Book 1.72 x 2.31 x 2.97 x 1.84 x 1.7 x 1.78 x
Nbr of stocks (in thousands) 20,704 20,704 20,704 23,304 23,304 23,304
Reference price 2 20.45 28.00 36.20 24.45 22.20 22.35
Announcement Date 02/04/19 14/04/20 16/03/21 08/03/22 06/03/23 14/03/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 384.4 417.5 398.1 312.6 321.9 280.5
EBITDA 1 46.33 45.87 42.28 22.23 24.44 9.48
EBIT 1 38.97 38.22 35.22 14.3 17.29 -4.259
Operating Margin 10.14% 9.16% 8.85% 4.57% 5.37% -1.52%
Earnings before Tax (EBT) 1 37.14 39.85 37.14 16.6 13.55 -3.032
Net income 1 28.34 30.87 29.77 13.7 9.552 -2.648
Net margin 7.37% 7.39% 7.48% 4.38% 2.97% -0.94%
EPS 2 1.360 1.480 1.430 0.5900 0.4099 -0.1136
Free Cash Flow 1 28.69 70.58 30.3 2.14 25.9 -17.18
FCF margin 7.46% 16.91% 7.61% 0.68% 8.05% -6.12%
FCF Conversion (EBITDA) 61.93% 153.86% 71.66% 9.63% 106% -
FCF Conversion (Net income) 101.24% 228.62% 101.76% 15.62% 271.17% -
Dividend per Share 2 1.262 1.341 1.102 0.4844 0.1800 -
Announcement Date 02/04/19 14/04/20 16/03/21 08/03/22 06/03/23 14/03/24
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 142 148 152 200 166 42.8
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 28.7 70.6 30.3 2.14 25.9 -17.2
ROE (net income / shareholders' equity) 12.1% 12.4% 11.8% 4.87% 3.11% -1.04%
ROA (Net income/ Total Assets) 7.22% 6.09% 5.63% 2.28% 2.51% -0.54%
Assets 1 392.3 507 529.2 601.6 380.3 489.5
Book Value Per Share 2 11.90 12.10 12.20 13.30 13.00 12.50
Cash Flow per Share 2 6.800 8.270 7.740 8.570 6.810 8.070
Capex 1 9.25 8.45 5.91 4.38 26.9 27.7
Capex / Sales 2.41% 2.02% 1.49% 1.4% 8.34% 9.89%
Announcement Date 02/04/19 14/04/20 16/03/21 08/03/22 06/03/23 14/03/24
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
WELGENE BIOTECH CO.,LTD. Stock Welgene Biotech Co.,Ltd.
+2.01% 16.34M
MODERNA, INC. Stock Moderna, Inc.
+43.36% 54.63B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 39.92B
LONZA GROUP AG Stock Lonza Group AG
+37.52% 38.82B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.86B
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.22B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.78B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12.21B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.16B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.94B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 6661 Stock
  4. Financials Welgene Biotech Co.,Ltd.